Barinthus Biotherapeutics Ownership 2024 | Who Owns Barinthus Biotherapeutics Now?

Institutional Ownership

25.17%

Institutional Holders

15.00

Barinthus Biotherapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ROYAL BANK OF CANADA	-	-	-	-1,000	-100.00%	-	Dec 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-100	-100.00%	-	Dec 31, 2023

Barinthus Biotherapeutics's largest institutional shareholder is ROYAL BANK OF CANADA, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ROYAL BANK OF CANADA	-	-	-	-1,000	-100.00%	-	Dec 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-100	-100.00%	-	Dec 31, 2023

The largest Barinthus Biotherapeutics shareholder by % of total assets is ROYAL BANK OF CANADA. The company owns 0.00 shares of Barinthus Biotherapeutics (VACC), representing 0.00% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-100	-100.00%	-	Dec 31, 2023
ROYAL BANK OF CANADA	-	-	-	-1,000	-100.00%	-	Dec 31, 2023

As of Dec 31 2023, Barinthus Biotherapeutics's largest institutional buyer is TOWER RESEARCH CAPITAL LLC (TRC). The company purchased -0.10K stocks of VACC, valued at -.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ROYAL BANK OF CANADA	-	-	-	-1,000	-100.00%	-	Dec 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-100	-100.00%	-	Dec 31, 2023

As of Dec 31 2023, Barinthus Biotherapeutics's biggest institutional seller is ROYAL BANK OF CANADA. The company sold -1.00K shares of VACC, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ROYAL BANK OF CANADA	-	-	-	-1,000	-100.00%	-	Dec 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-100	-100.00%	-	Dec 31, 2023

Barinthus Biotherapeutics's largest sold out institutional shareholder by shares sold is ROYAL BANK OF CANADA, sold -1.00K shares, valued at -, as of undefined.

Barinthus Biotherapeutics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
ETF Managers Trust	0.00%	10,133	-	-	Dec 31, 2023
FIDELITY CONCORD STREET TRUST	0.00%	11,568	-	-	Feb 29, 2024
NATIONWIDE MUTUAL FUNDS	0.00%	1,407	-	-	Jan 31, 2024
TRUST FOR PROFESSIONAL MANAGERS	0.00%	2,523	2,103	500.71%	Feb 29, 2024

Barinthus Biotherapeutics's largest mutual fund holder by % of total assets is "ETF Managers Trust", owning 10.13K shares, compromising 0.00% of its total assets.

Barinthus Biotherapeutics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
31 Mar, 24	15	-
31 Dec, 23	15	-6.25%
30 Sep, 23	16	6.67%
30 Jun, 23	15	15.38%
31 Mar, 23	13	-13.33%
31 Dec, 22	15	36.36%
30 Sep, 22	11	-8.33%
30 Jun, 22	12	20.00%
31 Mar, 22	10	-33.33%
31 Dec, 21	15	-
30 Sep, 21	15	-21.05%
30 Jun, 21	19	-

As of 31 Mar 24, 15 institutions are holding Barinthus Biotherapeutics's shares, representing an increase of 0.00% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
31 Mar, 24	9,698,209	-0.21%
31 Dec, 23	9,718,135	0.12%
30 Sep, 23	9,706,658	-1.43%
30 Jun, 23	9,847,143	-3.54%
31 Mar, 23	10,208,776	-0.19%
31 Dec, 22	10,228,507	1.31%
30 Sep, 22	10,095,963	60.30%
30 Jun, 22	6,298,127	36.11%
31 Mar, 22	4,627,371	-6.36%
31 Dec, 21	4,941,592	0.30%
30 Sep, 21	4,927,049	6.42%
30 Jun, 21	4,629,642	-

Barinthus Biotherapeutics (VACC) has 9.70M shares outstanding as of 31 Mar 24, down -0.21% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
31 Mar, 24	25.17%	3.96%
31 Dec, 23	25.22%	3.97%
30 Sep, 23	25.19%	3.83%
30 Jun, 23	25.65%	3.53%
31 Mar, 23	26.95%	3.57%
31 Dec, 22	27.46%	3.74%
30 Sep, 22	27.11%	9.46%
30 Jun, 22	16.93%	10.94%
31 Mar, 22	12.44%	3.42%
31 Dec, 21	19.08%	9.54%
30 Sep, 21	14.14%	4.09%
30 Jun, 21	18.60%	-

As of 31 Mar 24, Barinthus Biotherapeutics is held by 25.17% institutional shareholders, representing a 3.96% growth compared to 31 Dec 23.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
31 Mar, 24	2	-33.33%
31 Dec, 23	3	-25.00%
30 Sep, 23	4	-20.00%
30 Jun, 23	5	-
31 Mar, 23	5	-
31 Dec, 22	5	150.00%
30 Sep, 22	2	-33.33%
30 Jun, 22	3	50.00%
31 Mar, 22	2	-50.00%
31 Dec, 21	4	-20.00%
30 Sep, 21	5	-73.68%
30 Jun, 21	19	-

2 institutional shareholders have increased their position in VACC stock as of 31 Mar 24 compared to 3 in the previous quarter (a -33.33% decrease).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
31 Mar, 24	3	50.00%
31 Dec, 23	2	-33.33%
30 Sep, 23	3	50.00%
30 Jun, 23	2	100.00%
31 Mar, 23	1	-66.67%
31 Dec, 22	3	-
30 Sep, 22	3	-
30 Jun, 22	3	-25.00%
31 Mar, 22	4	-33.33%
31 Dec, 21	6	50.00%
30 Sep, 21	4	-
30 Jun, 21	-	-

3 institutional shareholders have reduced their position in VACC stock as of 31 Mar 24 compared to 2 in the previous quarter (a 50.00% increase).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
31 Mar, 24	15	-	9,698,209	-0.21%	25.17%	3.96%	2	-33.33%	3	50.00%
31 Dec, 23	15	-6.25%	9,718,135	0.12%	25.22%	3.97%	3	-25.00%	2	-33.33%
30 Sep, 23	16	6.67%	9,706,658	-1.43%	25.19%	3.83%	4	-20.00%	3	50.00%
30 Jun, 23	15	15.38%	9,847,143	-3.54%	25.65%	3.53%	5	-	2	100.00%
31 Mar, 23	13	-13.33%	10,208,776	-0.19%	26.95%	3.57%	5	-	1	-66.67%
31 Dec, 22	15	36.36%	10,228,507	1.31%	27.46%	3.74%	5	150.00%	3	-
30 Sep, 22	11	-8.33%	10,095,963	60.30%	27.11%	9.46%	2	-33.33%	3	-
30 Jun, 22	12	20.00%	6,298,127	36.11%	16.93%	10.94%	3	50.00%	3	-25.00%
31 Mar, 22	10	-33.33%	4,627,371	-6.36%	12.44%	3.42%	2	-50.00%	4	-33.33%
31 Dec, 21	15	-	4,941,592	0.30%	19.08%	9.54%	4	-20.00%	6	50.00%
30 Sep, 21	15	-21.05%	4,927,049	6.42%	14.14%	4.09%	5	-73.68%	4	-
30 Jun, 21	19	-	4,629,642	-	18.60%	-	19	-	-	-

Barinthus Biotherapeutics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jun 28, 2023	Scheeren Joseph	director	-	P-Purchase	Buy	10,000	$2.44	$24.40K	23,000
Jun 01, 2023	Wright Robin	director	-	P-Purchase	Buy	13,750	$2.66	$36.61K	48,256
Mar 29, 2023	Enright William	director, officer	Chief Executive Officer	S-Sale	Sell	15,000	$2.42	$36.30K	728,454

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source
Jun 28, 2023	Scheeren Joseph	director	-	P-Purchase	Buy	10,000	$2.44	$24.40K	23,000
Jun 01, 2023	Wright Robin	director	-	P-Purchase	Buy	13,750	$2.66	$36.61K	48,256

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source
Mar 29, 2023	Enright William	director, officer	Chief Executive Officer	S-Sale	Sell	15,000	$2.42	$36.30K	728,454

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jan 04, 2024	Pelletier Nadege	officer	Chief Scientific Officer	A-Award	Buy	105,000	$3.70	$388.50K	105,000
Jan 04, 2024	Griffiths Graham	officer	Chief Business Officer	A-Award	Buy	96,500	$3.70	$357.05K	96,500
Jan 04, 2024	Enright William	director, officer	Chief Executive Officer	A-Award	Buy	443,981	$3.70	$1.64M	443,981
Jan 04, 2024	Brown Gemma	officer	Chief Financial Officer	A-Award	Buy	193,000	$3.70	$714.10K	193,000
Jun 28, 2023	Scheeren Joseph	director	-	P-Purchase	Buy	10,000	$2.44	$24.40K	23,000
Jun 01, 2023	Wright Robin	director	-	P-Purchase	Buy	13,750	$2.66	$36.61K	48,256
May 12, 2023	Wright Robin	director	-	A-Award	Buy	19,197	$2.27	$43.58K	19,197
May 12, 2023	Scheeren Joseph	director	-	A-Award	Buy	19,197	$2.27	$43.58K	19,197
May 12, 2023	Phillips Anne M.	director	-	A-Award	Buy	19,197	$2.27	$43.58K	19,197
May 12, 2023	Morgon Pierre A.	director	-	A-Award	Buy	19,197	$2.27	$43.58K	19,197
May 12, 2023	Hammacher Alex	director	-	A-Award	Buy	19,197	$2.27	$43.58K	19,197
May 12, 2023	DAWES KAREN A	director	-	A-Award	Buy	19,197	$2.27	$43.58K	19,197
Mar 29, 2023	Marshall Margaret	officer	Chief Medical Officer	A-Award	Buy	60,000	$2.40	$144.00K	60,000
Mar 29, 2023	Evans Thomas George	officer	Fmr Chief Scientific Officer	A-Award	Buy	125,000	$2.40	$300.00K	125,000
Mar 29, 2023	Enright William	director, officer	Chief Executive Officer	S-Sale	Sell	15,000	$2.42	$36.30K	728,454
Feb 24, 2023	Pelletier Nadege	officer	Chief Scientific Officer	A-Award	Buy	485,000	$2.90	$1.41M	485,000
Feb 24, 2023	Pelletier Nadege	officer	-		Buy	-	-	-	-
Feb 23, 2023	Griffiths Graham	officer	Chief Business Officer	A-Award	Buy	105,000	$2.40	$252.00K	105,000
Feb 23, 2023	Enright William	director, officer	Chief Executive Officer	A-Award	Buy	440,000	$2.40	$1.06M	440,000
Feb 23, 2023	Ellis Christopher	officer	Chief Operating Officer	A-Award	Buy	105,000	$2.40	$252.00K	105,000

The last insider sell of Barinthus Biotherapeutics's stock was made by Enright William on Mar 29 2023, selling 15,000 shares at $2.42 per share (valued at $36.30K). The last insider buy of VACC was made by Scheeren Joseph on Jun 28 2023, buying 10,000 shares at $2.44 per share (worth $24.40K).

Barinthus Biotherapeutics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2024	4	-	-
Q2 2023	8	-	-
Q1 2023	7	1	700.00%
Q3 2022	3	10	30.00%
Q2 2022	9	3	300.00%
Q1 2022	7	-	-
Q4 2021	2	4	50.00%
Q2 2021	30	20	150.00%

4 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Barinthus Biotherapeutics's insiders, as of Q1 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2024	-	-	-
Q2 2023	2	-	-
Q1 2023	-	1	-
Q3 2022	-	7	-
Q2 2022	1	2	50.00%
Q1 2022	1	-	-
Q4 2021	2	-	-
Q2 2021	8	-	-

As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Barinthus Biotherapeutics's stocks.

Barinthus Biotherapeutics Peer Ownership

Ticker	Company
CYT	Cyteir Therapeutics, Inc.
MGTA	Dianthus Therapeutics, Inc.
TALS	Tourmaline Bio, Inc.
CGEM	Cullinan Oncology, Inc.
RVMD	Revolution Medicines, Inc. Warrant
ACHL	Achilles Therapeutics plc
VOR	Vor Biopharma Inc.
EWTX	Edgewise Therapeutics, Inc.
STOK	Stoke Therapeutics, Inc.
CTMX	CytomX Therapeutics, Inc.
SPRO	Spero Therapeutics, Inc.
CSBR	Champions Oncology, Inc.
GRPH	LENZ Therapeutics, Inc.
TYRA	Tyra Biosciences, Inc.
CCCC	C4 Therapeutics, Inc.
ASMB	Assembly Biosciences, Inc.
MNOV	MediciNova, Inc.
DSGN	Design Therapeutics, Inc.
THRD	Third Harmonic Bio, Inc.
ANEB	Anebulo Pharmaceuticals, Inc.
MOLN	Molecular Partners AG
NLTX	Neurogene Inc.
ACET	Adicet Bio, Inc.
TIL	Instil Bio, Inc.

VACC Ownership FAQ

Who Owns Barinthus Biotherapeutics?

Barinthus Biotherapeutics is owned by institutional shareholders (25.17%), insiders (0%), and public (0%). The largest institutional shareholder of Barinthus Biotherapeutics is ROYAL BANK OF CANADA (0% of total shares) and the top mutual fund owner is ETF Managers Trust (0.00% of total shares).

Who are the major institutional shareholders of Barinthus Biotherapeutics?

Barinthus Biotherapeutics's major institutional shareholders are ROYAL BANK OF CANADA, and TOWER RESEARCH CAPITAL LLC (TRC). The top five shareholders own together 0% of the company's share outstanding.

How many Barinthus Biotherapeutics shareholders are there?

As of Mar 2024, there are 15 institutional shareholders of Barinthus Biotherapeutics.

What percentage of Barinthus Biotherapeutics is owned by ROYAL BANK OF CANADA?

ROYAL BANK OF CANADA owns 0 shares of Barinthus Biotherapeutics, representing 0% of the company's total shares outstanding, valued at $0 (as of Dec 2023).

What percentage of Barinthus Biotherapeutics is owned by TOWER RESEARCH CAPITAL LLC (TRC)?

As of Dec 2023, TOWER RESEARCH CAPITAL LLC (TRC) holds 0 shares of Barinthus Biotherapeutics (VACC), compromising 0% of the company, valued at $0.